Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas

Journal of Neuro-Oncology

Volumn 27, Issue 2, 1996, Pages 117-126

  Chozick, Bruce S ^a   Benzil, Deborah L ^a,c   Stopa, Ed G ^b   Pezzullo, John C ^b,d   Knuckey, Neville W ^a   Epstein, Mel H ^a   Finkelstein, Sydney D ^b,e   Finch, Paul W ^a,f  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Arachnoid; Differentiation; Immunohistochemistry; Malignancy; Meningioma

Indexed keywords

GENE PRODUCT; MEMBRANE PROTEIN; PROTEIN P53;

ARTICLE; BRAIN ARACHNOID; BRAIN CELL; BREAST CARCINOMA; CARCINOGENESIS; CELL TRANSFORMATION; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MENINGIOMA; ONCOGENE NEU; TUMOR CELL;

EID: 0030052024     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00177474     Document Type: Article

References (30)

1. Russell DS, Rubinstein LJ: Pathology of tumors of the nervous system. Baltimore, Williams & Wilkens, 1989, ed 5, pp 449-529
2. Bickerstaff ER, Small JM, Guest IA: The relapsing course of certain meningiomas in relationship to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 21 : 89-91,1958
3. Jay JR, MacLaughlin DT, Riley KR, Martuza RL: Modulation of meningioma cell growth by steroid hormones in vitro. J Neurosurg 62: 750-756, 1985
4. Martuza RL, Miller DC, MacLaughlin DT: Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas. J Neurosurg 62: 750-756, 1985
5. Olson JJ, Beck DW, Schlechte J, Loh PM: Hormonal modulation of meningioma in vitro. J Neurosurg 65: 99-107, 1986
6. Knuckey NW, Stoll J, Epstein MH: Intracranial and spinal meningiomas in patients with breast carcinoma: Case reports. Neurosurg 25: 112-117, 1989
7. Schoenberg BS, Christine BV, Whisnant JB: Nervous system neoplasms and primary malignancies of other sites: The unique association between meningiomas and breast cancer. Neurology 25: 705-712,1984
8. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Pak JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard M, Kuang W-J, Wood WI, Goeddel DV, Vandlen RL: Identification of heregulin, a specific activator of p185ereB2. Science 256: 1205-1210,1992
9. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Ben Levy R, Koski RA, Lu HS, Yarden Y: Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69: 559-572,1992
10. Marchionni MA, Goodearl ADJ, Chen MS, BerminghamMcDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhatler J, Kobayashi K, Wroblewski D, Lynch C, Baldassare M, Hues I, Davis JB, Hsuan J, Totty NF, Otsu M, McBurney RN, Waterfield MD, Stroobant P, Gwynne D: Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362: 312-318, 1993
11. Bargmann CI, Hung M-C, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45: 649-657,1986
12. Segatto O, King CR, Pierce JH, DiFiore PP, Aaronson SA: Different structural alterations up-regulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8: 5570-5574,1988
13. DiFiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182,1987
14. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712,1989
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig W: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311,1991
16. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992
17. Holstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53,1991
18. Iggo R, Gatter K, Bartek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679,1990
19. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539,1988
20. Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245,1992
21. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83,1992
22. Andersen TT, Holm R, Nesland JM, Heimdal KR, Ottestad L: Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 68: 540-548,1993
23. Callahan R: p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst 84: 826-827,1992
24. Rubinstein LJ: Tumors of the central nervous system. In: Atlas of Tumor Pathology, Bethesda, Armed Forces Institute of Pathology, 2nd series, Fascicle 6,1972
25. Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Henessy C, Gullick WJ, Tuzi NL, May FEE, Westley BR, Horne CHW: NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 161:15-25,1990
26. Singleton TP, Niehans GA, Gu F, Litz GE, Hagen K, Qui Q, Kiang DT, Strickler JG: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23: 1141-1150,1992
27. Banks L, Matlashewski D, Crawford L: Isolation of human p53-specific monoclonal antibodies and their use in the study of human p53 expression. Eur J Biochem 159: 529-534, 1986
28. Chozick BS, Weicker ME, Pezzullo JC, Jackson CL, Finkelstein SD, Ambler MW, Epstein MH, Finch PW: Pattern of mutant p53 expression in human astrocytomas suggests the existance of alternate pathways of tumorigenesis. Cancer 73: 406-415, 1994
29. Porter PL, Gown AM, Kamp SG, Coltrera MD: Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed tissue. Am J Pathol 140: 145-153, 1992
30. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98: 503-517,1975